

How to Cite:

Alsuwaileh, A. N., Albakheet, I. A. I., Aljaloud, H. A., Aljadeedi, A. K., Alyami, S. H., & Alrashed, A. H. M. (2024). The role of pharmacogenomics in personalized medicine: A focus on drug metabolism. *International Journal of Health Sciences*, 8(S1), 1844–1859. <https://doi.org/10.53730/ijhs.v8nS1.15423>

The role of pharmacogenomics in personalized medicine: A focus on drug metabolism

Ali Nasser Alsuwaileh

KSA, National Guard Health Affairs

Ibrahim Abdulaziz Ibrahim Albakheet

Albakheet- Public Health

Hammad Abdullah Aljaloud

KSA, National Guard Health Affairs

Abdullah Khalifah Aljadeedi

KSA, National Guard Health Affairs

Saeed Hassan Alyami

KSA, National Guard Health Affairs

Abdulaziz Hussain Mohammed Alrashed

National Guard Health Affairs

Abstract--Background: The conventional model of drug treatment may involve set protocols of drug use and not the currently variegated pharmacology patterns due to mutations in drug metabolism enzymes. But recent innovations in pharmacogenomics have provided new insight on feeds and processing of drugs through genetic and environment components that present a more divergent view of treatment. **Aim:** The purpose of this study is to understand drug metabolism specificity in the framework of individualized medicine and its potential to enhance the efficacy and safety of a drug due to genetic and lifestyle differences. **Methods:** A literature search was performed to compare the effects of genetic variations and environment as to drug metabolism. The research also focuses at how the pharmacogenomics testing is used in developing the custom drug therapies. **Results:** major impact in the rate of metabolism of drugs along with their effectiveness and toxicity. Of course, assessing health-promoting behaviours that include diet and physical activity, or the lack of thereof, as well as others, can strongly impact therapeutic success. **Conclusion:** Potential for manufactured Meal is

its ability to highlight the vests in drug metabolism that are crucial for finding personalized treatments. Through the use of pharmacogenomics testing in medical practice, recommenders can enhance safety and effectiveness indicating a better patient outcome.

Keywords--Pharmacokinetics, pharmacogenomics, gene-pharmacotherapy, genetic differences, side effects of drugs, pharmacogenomics analysis.

Introduction

Pharmacological field has tended to practice the treatment based on the principle that one size fits all, where most patients receive the same medications and doses. Nevertheless, recent research in pharmacogenomics dictated considerable importance to the drug metabolism variation to the general outcomes of the therapies. Pharmacokinetics, the rate and manner that the body handles medications, are different across users. The pharmacogenomics model suggests that there are genetic variations, which were coupled with other factors like diet, and lifestyle and age to explain the way in which individuals metabolize drugs. These variabilities can hence result in variation in the effectiveness and toxicity of the drugs which makes it important to embrace personalized medicine. By understanding the factors that cause variation in drug metabolism genes and environment, a doctor is in a good position to recommend a drug of most appropriate efficacy and least side effect in a gentleman. This paper aims at examining the idea of drug metabolism interpersonal difference and the importance of these discoveries for the contemporary generation of individualized medicine approaches. [1,2]

An explanation of what genetic differences are and how they affect the metabolism of a drug

Polymorphisms drug metabolism Polymorphisms are variations in genes within individuals and are said to be critical in providing information on how a certain medicine can or cannot be metabolized in the body. These differences exist in the genes of enzymes, transporters, and receptors located in the biopharmaceuticals' absorption, distribution, metabolism, and excretion (ADME) system. Of these, the largest body of work has been dedicated to the cytochrome P450 (CYP) enzyme family, which metabolizes over 70 percent of the drugs in clinical use. Polymorphisms exist in CYPs like CYP2D6, CYP2C9, and CYP2C19 therefore putting patients into categories with poor metabolism, intermediate metabolism, normal metabolism, and ultra rapid metabolism. For example, a man with a nonfunctional CYP2D6 gene may get little benefit or high toxicity of drugs such as codeine or tamoxifen and a woman with the ultra-rapid CYP2D6 gene may clear the drug from her system before it can be effective.[3,4] The variations in the gene therefore have even wider implications that affect drug transporters for instance P-glycoprotein encoded by the ABCB1 gene and receptors including the vitamin K epoxide reductase complex (VKORC1). Polymorphisms in ABCB1 can actually affect the absorption and distribution of drugs such as digoxin or anti-cancer agents. Likewise, genetic variability identified in the gene encoding vitamin K

epoxide reductase complex subunit 1 (VKORC1) can have a direct impact on the sensitivity of patients to warfarin and as a result must involve dose titration based on genotyping. [5] These genetic differences explain why the pharmacogenomics tests are important as they help clinicians determine how a patient will metabolize the drugs, which drug reactions the patient is likely to have, and which drugs will work best in treating illness.[6]

Moreover, multiple gene and environment interactions complicate drug metabolism which poses a challenge when prescribing drugs. For instance, people with genetic polymorphism may need to readjust the drug metabolism because of interactions with other drugs, food products or exacerbating pathologic conditions. This showcases why it takes more than pharmacogenomics data to adapt it to clinical and lifestyle data for an individual patient. The study goes on and new variants are identified over time which make the scope of the impact of genetic profiles in drug metabolism even broader, opening the door for better and more tailored approaches to health care.[7]

Pharmacogenomics: Tools for Optimizing Therapeutic Benefits

Pharmacogenomics is a flagship model of personalized medicines and encompasses a unique concept of targeting treatment outcomes to the genetic makeup of an individual. Genetic differences play a very important role in understanding how different patients respond to different drugs in terms of metabolism, therapeutic effects and toxic effects. The molecular information derived from pharmacogenomics studies thus provides the healthcare professionals the opportunity to shift from this one size fits all mentality to a much more strategic approach that ensures, on the one hand, the maximal therapeutic effects of the drugs and on the other reduces the probability of side effects as much as possible. For example, pharmacogenomics studies can be used to determine genetic factors that determine which patients will likely benefit from use of a certain drug and which patients will need a different dosage schedule. This is more relevant especially in handling complicated illnesses such as cancer, cardiovascular diseases, and mental health illnesses in that drug impacts differ from one client to another. [8,9]

Pharmacogenomics in practice can be illustrated through the most representative example of the targeted therapies, which are applied for cancer. This is because drugs such as trastuzumab for HER2 positive breast cancer are only given to patients with HER2 receptor positive tumors. Likewise, pharmacogenomics has revolutionized the handling of therapeutic with narrow margins of safety such as the use of warfarin. CYP2C9 and VKORC1 pharmacokinetic testing helps the clinician identify the right starting dose and so helps avoid bleeding or thromboembolic events. This approach does not only enhance the safety of patients but also shortens the process that takes when administering an appropriate drug and its correct dosage. In addition to the issue of treatment effectiveness, pharmacogenomics is crucial in stopping serious ADRs, which remains one of the major causes of morbidity and mortality. Genetic testing can identify patients at risk of severe ADRs, such as hypersensitivity reactions to carbamazepine or batcaver, by detecting HLA-B15:02 and HLA-B57:01 alleles respectively. Clinicians' decisions to avoid specific drugs that are potentially

dangerous will reduce adverse effects and increase patient compliance or therapy. In addition, the application of pharmacogenomics in prescribing leads to the decrease in the healthcare spending on hospitalizations and treatment of condition that arises from side effects of drugs. [10]

While the indications of how to ensure maximum effectiveness of an administered drug are still being explored, there is a sense that pharmacogenomics research is opening up new possibilities. Multiple genetic variant or polygenic risk scores are more effective in assessing drug responses than single genetic variant. Pharmacogenomics implementation within EHRs also enhances clinical decision support in real-time through delivery of personalized interventions at the point care. That is why ongoing improvements make pharmacogenomics more available than before; though some challenges still persist for example high costs of genetic tests and the need to develop stringent clinical reference levels. Lastly, there are expectations of advancement of pharmacogenomics within routine prescribing in regards to 'personalized medicine' and improved health care. [11]

Linking Human Genomics and therapeutics for Personalized Medicine

Genetics brought into the practice of medicine new paradigms for constructing individualized approaches to treatment, establishing the new epoch in medical practice. It is referred to as precision or personalized medicine, wherein the ability of an individual to respond to certain medications, features of disease and therapeutic effects are first forecasted based on their genetic structure. Translating genetics to medicine extends the current medical practice by allowing clinicians envision a diagnostic and therapeutic approach that interfaces with an individual's biology. This shift in paradigm also directly translates to reduction of adverse effects due to wrong or non responsive treatments.[12] An Important area where genetics come in handy is in pharmacogenomics, in terms of how gene differences manifest themselves in terms of drug response. Pharmacogenomics can show if a patient is a non-responders or has moderate or highly rapid rate of metabolism to some drugs including antidepressants, pain relievers, chemotherapy drugs, among others. For instance, patients with CYP2C19 variations may need different dosing or even different medication when using products like clopidogrel a blood thinner used to prevent heart attacks and other cardiovascular complications. Likewise, oncology treatment has advanced remarkably with genetic testing which includes the therapeutic agents like Imatinib to chronic myeloid leukemia or sumatriptan in EGFR mutated lung cancer because this technique is targeted and cost-effective, less hazardous have a higher potential for cure.[12]

Besides, drug response, genetic information will be useful in proactive diagnosis of diseases to which one is most likely to be prone. For example, people with BRCA1 or BRCA2 genes can get information of screening and early preventing plan of breast and ovarian cancer. In addition, with today's powerful technologies such as whole-genom and exom sequencing, clinicians are able to look for rare genetic diseases or multiple genetic predisposing factors towards common diseases to improve the diagnostic precision and treatment planning. [13] Main issues of genetic integration into medicine include multidisciplinary cooperation as well as organization. Physicians, genetic counselors and pharmacologists as

well as bioinformaticians coordinate the interpretation and application of genetic data in clinical practice. This relationship guarantees that we capture the unique features of images meaning that genetic information is well explained, and informed choice is made, and patients well educated. Furthermore, genetic data can now be integrated into the treatment Iter process with the help of newly developed digital tools and electronic health records (EHRs) .Still some of the issue persist which are, cost of the genetic testing, ethical issues and inequality in genetic based treatments and diagnosis. To address these barriers, more funding, education, and focused policy to advance these goals for the elimination of barriers to genetic services are needed. Lastly, the connection between genetics and medicine is about the future of medicine and how disease can be diagnosed, treated and prevented, in other words how medicine can be tailored and made precise.[13]

Pharmacogenomics And Its Role in the Development of Precision Medicine

Pharmacogenomics is an important part of the precision medicine since it allows adapting the required therapy depending on a patient's genes. This is quite different from the usual treatment, which starts with treatment modalities formulated with treatments that cater for the average patient without considering their genetics and the rate at which their body will metabolize pharmacogenomics. This framework guarantees that clients get the correct drug in the correct amount, aiming at reducing effective drug reactions and boosting valuable therapeutic total results. Pharmacogenomics is a direct combination of genetic science and clinical practice which has revolutionized disease management and treatment to a patient-oriented model. The best example of pharmacogenomics contribution to precision medicine involves the genetic variation that affects drug metabolism. For instance, the cytochrome P450 (CYP) enzyme family is well known to be involved basically with the metabolic process of most drugs. Polymorphisms in CYP genes including: CYP2D6, CYP2C9 and CYP2C19 affect the activity of these enzymes and thus bring about considerable genetic difference in drug metabolism. For instance, patients who have genetic variations in CYP2D6 metabolize antidepressants or opioids too rapidly or too slowly, affecting drug effectiveness or generating toxicity. The pharmacogenomics testing can help clinicians to modify medication therapy based on the results allowing for the best therapeutic effects with the lowest risk possible.[14]

In oncology, pharmacogenomics has played a critical role in the development of target therapies which is a signature of precision medicine. Pharmacogenomics has made significant advances in cancer treatment, peripheral examples include; trastuzumab which is used in treating HER2 positive breast cancer or imatinib which targets chronic myeloid leukemia with specific gene mutations. Such therapies are prescribed depending on the presence of genetic markers implying that the therapies will work for patients who possess the right molecular signature. Furthermore, pharmacogenomics information is being used in the solution of drug resistance, one of the major problems in the treatment of cancer by pointing out new routes or suggesting an appropriate set of drugs according to the patient's genes.[15] Pharmacogenomics also supports precision medicine regarding lowering ADR rates, one of the prime causes of readmissions and costs. Genetic testing for variants in HLA genes, such as HLA-B57:For example,

knowing from which gene, such as HLA-B*01 or HLA-B15:02, individuals are at risk from hypersensitivity reactions to drugs such as batcaver or carbamazepine, enables doctors not to prescribe it to at-risk individuals. It also increases patient safety and strict compliance with adherent regimes as the risk of side effects are minimized. Furthermore, pharmacogenomics is pivotal in the control of chronic illnesses that demand extended drug treatment. For diseases such as hypertension or diabetes, diagnoses of psychiatric disorders, or many others, genetic testing assists in determining the best drug to use and the correct dosage, NOT involving a process taking much time given that the patient's lives will be improved In the process. For instance, polymorphisms in SLCO1B1 which reflects statin metabolism, can inform management of lipid profile and avoid statin induced myopathy.[15]

While pharmacogenomics is an emerging discipline, data in EHRs and new developments in genomic technologies are promoting precision medicine. Additional work to establish pharmacogenomics databases and protocols also add to simplification of its use in daily practice. However, issues including costs, availability and the issue of awareness and knowledge among most of the practitioners and patients present some of the major issues that hinder the enough embracing of the innovation. Solving these problems is crucial to optimizing the use of pharmacogenomics in changing the healthcare process.[16] In conclusion, pharmacogenomics may be viewed as the best primary example of the concept of precision medicine that suggests the scientific approach to individualized pharmacotherapy. Thus, the population of patients receiving appropriate drug treatment, as well as the genetic variability of the effectiveness of medication, opens the door to the future in which medical treatment will be carried out based on the genetic characteristics of the body. It not only ensures improved clients' throughputs or improved condition from the disease but also work to ensure that the global health systems are made more efficient and sustainable.

Personalized Drug Therapy: The Pharmacogenomics Approach

According to the principles of pharmacogenomics, the concept of individualized drug treatment is clearly on the forefront of the new millennium trends. This approach involves using the information about the person's genetically determined metabolism of a specific drug in order to prescribe the best dose and sort of drug. Different from conventional treatment approaches, which mostly involve the prescription of drugs in an empirical fashion, this forecasted model of pharmacogenomics entails genetic profiling to determine a particular patient's capability to metabolize particular medication. This not only improves the quality of operations and procedures, but also minimizes the likelihood of side effects and diminishes the amount of useless treatments most importantly it minimizes the cost of healthcare.[17] Pharmacogenomics is the scientific discipline which supports an individualized approach to treatment through examination of genetic factors that affect drug metabolism. For instance, the polymorphic genes CYP2C19 which involve the metabolism of clopidogrel, an antiplatelet drugs used for prevention of cardiovascular events. Reduced-function variants in patients may fail to activate the drug as required hence making it to be less effective and thus exposed to bad results. Such genetic differences are ascertainable through

testing; the clinician can then recommend a different drug or even a different dosage so that the patient can get the best form of treatment. Likewise, genetic mutations in the TPMT gene affect the ability to metabolize thiopurine drugs that are used to treat leukemia and autoimmune disease. Getting tested for these variants means having the right dose with measures that can prevent toxicity that may be lethal.[18]

The pharmacogenomics approach also applies to treatment of side effects and ways of minimizing ADRs. Major gene variations for drug hypersensitivity are the HLA-B alleles, for example, batcaver or carbamazepine. Measuring these markers prior to commencing such therapy prevents adverse reactions that might be life-threatening and enhances patient outcomes. The paradigm of pharmacogenomics-guided therapies in oncology, such as HER2-positive breast cancer and BRAF gene mutation melanomas treated with trastuzumab and vemurafenib respectively, show how on the basis of genetic data therapies may be selected resulting in enhanced survival. Furthermore, the pharmacogenomics concept contributes positively to the treatment of chronic illnesses that require extended drug therapies. For example, testing for SLCO1B1 variants in patients taking statins to diagnose patients with predisposition to statin-induced myopathy facilitates prescriber selection of safer drug options. Likewise, genetic testing of CYP2D6 and CYP2C19 polymorphisms guides the appropriate choice of antidepressant and dosage in psychiatric disorders and saves time required for clinical improvement.[19] Pharmacogenomics in the application of personalized drug action in also enhances patient oriented care. Patients want to be involved in their treatment process, and by giving patients genetic information, clinicians can build trust with them and ensure that the patient will follow the plan. Further, pharmacogenomics information can be integrated into EHR and provide decision support tools to later apply individualized approach to chronic patient care, as well as, providing efficient communication between healthcare professionals.[20]

However, there is more evidence demonstrating the effectiveness of the pharmacogenomics-based personalized therapy approach, yet multiple barriers remain: the cost of genetic testing, provider knowledge about pharmacogenomics, and unequal access to genetic services. But constant emergence in new Genomic technologies and the work being done towards creating protocols for its implementation is making pharmacogenomics accessible. Over time and with increasing research, most pharmacogenomics biomarkers will be further established and involve more patients in personalized drug therapy.[21] In its turn, the approach based on pharmacogenomics of individuals defines the idea of the right drug therapy for each person and reflects the further development of medicines. When issues of genomics are combined with the provision of healthcare to the patients, medical practice is made safer, more effective and focused on the individual patient making the whole idea set to revolutionize healthcare and enhance health status all across the world.

Researching Gene Factors Affecting Drug Response and Toxicity

Pharmacogenomics has developed into a focus of studying in order to determine the genetic basis of drug response efficacy and toxicity. This [it stands to reason that] genetic polymorphisms affect the pharmacokinetics of drugs as well as the

effect, effectiveness and toxicity associated with different drugs, resulting in variations in therapeutic outcomes and ADRs. These differences are frequently due to single base pair differences known as single nucleotide polymorphisms (SNPs) in genes that code for drug-metabolizing enzymes, transporters and receptors and are the basis for the prediction of individual drug responses. In this way, the genetic options can help researchers and clinicians to perfect the therapy plans, by having access to treatments that will be both effective for the patient and not cause any harm.[22] One of the important ways that genetics brings differences in drug metabolism is through difference in drug metabolizing enzymes especially in the Cyp450 family. For instance, CYP2D6_A_ can make a human being act as a poor metabolizer, intermediate metabolizer, extensive metabolizer, or ultra-rapid metabolizer. Such differences affect drug-metabolizing enzymes such as antidepressants, beta-blockers, and opioids. Patients who metabolize a drug slowly may be exposed to toxic levels of a drug or substance thus developing side effects while those who metabolize the same drug rapidly may clear the drug or substance faster hence it may not have any effective therapeutic effect. The same holds true for the other enzymes including CYP2C19 involved in the metabolic reaction of clopidogrel, which is an antiplatelet drug.[22] Drug transporters through which drugs enter and exit cells are another important focus of genetics with regard to drug pharmacokinetics. Polymorphisms in the SLCO1B1 gene that codes for the OATP1B1 transporter influence the kinetics of statin uptake in the liver. Statin use increases the occurrence of myopathy more in patients with reduced-function variants hence recommending genetic test before beginning a course on statins. Further, apparently genetic variations in ABCB1 gene coding for P-glycoprotein may influence the distribution and metabolism of drugs, the effectiveness of their treatment of diseases like cancer and epilepsy.

SNPs also affect drug targets-receptors and enzymes on which a drug acts and through which it produces its effect. For example, EGFR gene biomarkers define whether tyrosine kinase inhibitors are effective for treating non-small cell lung cancer. Likewise, polymorphic dialects of the target of warfarin, the VKORC1 gene, make variation difference in sensitivity to warfarin that calls for dose refinement to avoid bleeding and clotting. The above cases are good examples of how genetics also define not only pharmacokinetics but also pharmacodynamics of drugs.[23] An important issue that is considered in medical practice – this is an adverse drug reaction, of which genetic aspects are traditionally associated. Rare alleles including types like HLA-B are also implicated to cause severe hypersensitivity reactions. For example, HLA-B57:01 is associated with batcaver hypersensitivity and HLA-B15:02 alleles are found in severe cutaneous reactions to carbamazepine. The two genetic markers are discerned through testing so that the clinician can avoid administering the high risk drugs to clients with the inherent susceptibility, hence enhancing the safety of the patients.[24] Investigating the role of genes in drug effectiveness and risks also relates with large health concerns. By genetic analysis of population subgroups, progression to therapies tailored for ethnicity and region could be made due to the concerns with the drug-screen behaviorism variations. For instance, there are increased prevalence of specific polymorphisms, CYP2C9 and VKORC1 in some populations to the influence warfarin metabolism. The findings described in the contributed papers can inform precise interventions targeting nuanced patient groups. [25]

Although the analysis of genetic factors that control drug response has advanced considerably, there are obstacles to that progress. The expensive rate of genetic tests, relative rarity of doctor's and patients' knowledge of the tests, and the difficulty of reading the results are among the JMHS's issues. However genetic cases are just one side of the coin while the other side includes environmental factors, lifestyle factors and combination effects of some other medications.[26] Consequently, evaluating genetic aspects such as patient response variability to drugs, and drug toxicity is essential in achieving personal medicine. So, genetic information can be used by clinicians in drug selection process to improve treatment efficacy, minimize potentially hazardous drug effects, and increase the chances for success. Future developments in this area of study are sure to extend the knowledge of genetic variation, which in turn will lead to better quality, risk-free and personal health care.

Introducing a New Approach to the Healthcare System Based on Personalized Pharmacology

Individualized medicine consists of targeted medication dosages which meet the general features of genetics and other attributes of each patient. Within this concept, program developers are no longer constrained by the idea of treatment for all, but treatment that has the least possible side effects and the best improvement rate possible. Personalized pharmacology is now in the process of achieving new standards of pinpoint accuracy and efficacy through the gains of pharmacogenomics, bioinformatics, and molecular diagnostics.[27] Perhaps the most obvious way in which personalized pharmacology is transforming medicine is genetics. In this knowledge management system, clinicians are able to determine how a patient is likely to react to certain chemicals in drugs based on genetic pattern of the individual. It also makes it possible to choose those drugs and their doses that would be most effective without posing the risk of creating side effects. For example, testing for the polymorphisms in the CYP2D6& CYP2C19 gene in patients developed for depression and antiplatelet treatments means that the physicians can give effective results. Similarly, oncologists can choose drugs based on tumor specific genetic markers like Her2/neu over expression to choose trastuzumab and has better survival with lesser toxicities.[28]

Personalized pharmacology also changes the approach to chronic diseases, which are characterized by long and often intricate treatment with use of drugs. For example, in cardiovascular medicine, genetic testing of SLCO1B1 variants enables computation of patients susceptible to statin-induced myopathy to make new treatment regimens. In diabetes treatment, pharmacogenomics aspects help to determine the medication, such as sulfonylureas or metformin, according to genetic profiles. These specific strategies improve compliance with therapy and long-term health results. Apart from self-advantages, personalized pharmacology has enormous opportunities to advance the popular health. This means that, through determination of the factors that need to be inherited for a particular variation to be correct in a given population, then population specific treatment programs can be developed. This is especially important given the fact that present day global trends indicate that certain genetic pockets within certain ethnic groups may not respond well to present line drug combo. For instance,

there exists genetic variations especially related to warfarin metabolism in particular ethnical groups and therefore, requires a change in dosing to have a huge cover crops and be efficient at the same time. Other such measures help in eradicating the problem of inequality in the treatment of patients.[29] Furthermore, analyzing people's genomes helps prevent adverse drug reactions (ADRs), which are the major reason for hospitalizations and increased expenses. Genotyping for the HLA-B alleles has helped avert severe adverse reactions to certain medications including batcaver and carbamazepine. In case of treatment planning, the at-risk patient population may be known before undergoing therapies that are ineffective or even toxic, which would benefit patient safety and also decrease the costs on healthcare.[30]

It also reaffirms the patient-centered medicine in which pharma placed an emphasis on it through adopting pharmacology. This inevitably makes patient more trusting, attentive and compliant with treatment decisions which would otherwise be unfulfilled due to lack of such genetic understanding. Furthermore, they found that the expansion of technologies, including EHRs incorporating pharmacogenomics data for clinical analysis and cross-professional collaboration, improve the quality of care that can be provided to patients.[31] There are, however, a number of issues which lie ahead of the implementation of the personalized pharmacology. The major challenges which have been identified include; expensive costs Of performance of the genetic tests, coupled with lack of expanded access in low economically developed areas, inadequate provider training. In addition, distributional equity based concerns such as privacy, data protection and genetic discrimination are major challenges that seek equitable and responsive intervention. In the future, as people conduct research in personalized pharmacogenomics and pharmaceutical technology develops deeper, the aspects of personal pharmacology will extend to include gene editing or RNA Based therapies etc. These innovations claim to be capable of treating diseases that were until now untreatable, and further increase the accuracy of medicine. Personalized pharmacology will change the approach to health and medicine administration by making it safer, more effective, and unique for each patient around the globe.[32]

Drug Metabolism Variability: John, The Roadmap to Optimal Outcomes

Pharmacokinetics, the differences in the rates of drug metabolism are the foundation of individualized approach to treatment based on the patient's genetic and physiological characteristics. Pharmacokinetics which is the study of how drugs are absorbed, distributed, metabolized and excreted by the body is affected by genetic factors, age, sex, organ function and exposure to certain factors. These differences are critical because they define how drugs will work, for better and for worse, in patients' bodies and dictates the result of treatments pegged on these medicines.[33] Personal variation in drug metabolizing enzymes is governed purely by genetic factors in terms of genetic polymorphisms. The CYP enzyme family that is involved in the metabolism of most drugs has been reported to vary so much from one individual to another. For instance, the genetic variation determines the CYP2D6 gene so that patients can be easily characterized as PMs, IMs, EMs, or UMs. Originally, drug efficacy and safety are embedded in these classifications. In effect, poor metabolizers were likely to have drug build up and

toxicity while ultra-rapid metabolizers were likely to exhibit poor efficacy due to rapid elimination. This alone points in part to the need for genetic testing in order to inform rational choice of drug and dosage. Another important enzyme subject to genetic polymorphism is CYP2C19 which includes clopidogrel and proton pump inhibitors in its list of metabolized medications. Those with reduced-function CYP2C19 receive a weaker activation of the medicine, thus increasing the likelihood of cardiovascular events. On the other hand, the effects of PPIs may be long-standing in these patients, making necessary, changes in the dosage. Such knowledge enables the clinician to deliver treatment that is effective as well as safe to the recipient of the treatment.[34]

Apart from hereditary influences, eating habits, tobacco, alcohol and some other drugs, additional medicines can influence the rate of drug metabolism. For example, grapefruit juice can delay the working of CYP3A4 enzyme thereby slowing up the metabolisms of statins and calcium channel blockers. Like it, smoking promotes expression of CYP1A2 that increases the metabolism of drugs like theophylline and some antipsychotic medications. Assurance of these interactions is important in order to fit treatments to a specific patient's life schedules. Inter-individual variability in drug metabolism is also seen in regard to specific populations. For example, the patients in children and elder groups may suffer from different metabolic capability than adults owing to a less developed or damaged organ system. This is the case because in neonates, the biotransformation enzyme systems are still immature, and hence the drug half-life is long, raising the risk of toxicity. On the other hand, hepatic and renal function may be compromised in elderly patients with a resultant increase in susceptibility to adverse effects through alteration of the dose rate. All of these age related issues have to be taken into account when planning therapy to avoid adverse effects of the treatment on the patient.[35]

Thus, sex-based difference in drug metabolism also emphasizes the importance of personalized therapy. Sex-based differences in hormonal regulation of drug-metabolizing enzymes are related to different rates of drug clearance. For instance, women may take some medicine like zolpidem slowly than men because of which it prolongs its action and increases the chances of side effects. All of these make it imperative to identify such differences in order to enhance gender specific treatment. The general importance of the inter-individual variability in drug metabolism is probably best illustrated by its relation to ADR. Metabolic inter-individual differences may create conditions within the body in which the drug concentration is too low to eradicate pathogens or too high to be safely tolerated. For example, patients with low TPMT enzyme activity are likely to develop serious bone marrow suppression when administered thiopurine drugs. Recognizing such genetic and metabolic distinctions facilitates prevention of such risks in the form of dose changes or various therapies. New pharmacogenomics test has brought forth metabolism predictors of drugs before the prescription stage, enabling precision treatment. These tests are very useful in predicting the likely impact of a person's genetic profile on drug metabolism then prescribe the appropriate drugs and the right dosage that is likely going to respond well. Since these technologies are growing more popular and cheap, their implementation into the clinical setting routine will also improve the capability of target care.[36,37,38] Therefore, variability in drug metabolism is one of the necessary

approaches to reaching individual therapy goals and maximal efficacy and safety. This insight into genetic, environmental, and physiology differences allows providers to break free from the éalu cliché mold of treatment and come up with innovative solutions that fit the patients' needs to a T. In doing so, this approach benefits the quality of care as well as becomes a foundation for the future where people rather than diseases will be treated.[39,40]

Conclusion

Therefore, it is safe to conclude that drug metabolism variation is one of the biggest reasons for the differences in personalized pharmacotherapy. With further knowledge in genetic variations affecting drug metabolism, it is slowly transitioning to the norm to have people receive treatment unique to them. Pharmacogenomics testing has the ability to enhance patient outcomes by determining drug susceptibility in patients, to get the right drug for the right person and right dose and also the wrong drug for the wrong patient and wrong dose. As technology progresses and different methods in genetic testing become available to a broader range of the population, healthcare providers are better equipped and more capable to make decisions that in addition to improving the outcomes of the cure, also prevents contra indications such as more negative reactions from occurring to the body when taking certain drugs. The inclusion of drug metabolism variability into clinical practice is a new revolution in the medical field that will pave way to better safety, effectiveness and patient tailored in the global society.

References

1. Adebukola, A. A., Navya, A. N., Jordan, F. J., Jenifer, N. J., & Begley, R. D. (2022). Cyber security as a threat to health care. *Journal of Technology and Systems*, 4(1), 32-64.
2. Bank, P. C., Swen, J. J., & Guchelaar, H.-J. (2018). Implementation of pharmacogenomics in everyday clinical settings. *Advances in Pharmacology*, 83, 219-246.
3. Brown, L., Eum, S., Haga, S. B., Strawn, J. R., & Zierhut, H. (2020). Clinical utilization of pharmacogenetics in psychiatry—perspectives of pharmacists, genetic counselors, implementation science, clinicians, and industry. *Pharmacopsychiatry*, 53(04), 162-173.
4. Cacabelos, R., Cacabelos, N., & Carril, J. C. (2019). The role of pharmacogenomics in adverse drug reactions. *Expert Review of Clinical Pharmacology*, 12(5), 407-442.
5. Carr, D. F., Turner, R. M., & Pirmohamed, M. (2021). Pharmacogenomics of anticancer drugs: Personalizing the choice and dose to manage drug response. *British Journal of Clinical Pharmacology*, 87(2), 237-255.
6. Cheng, J. W. (2018). Current perspectives on the role of the pharmacist in heart failure management. *Integrated Pharmacy Research and Practice*, 1-11.
7. Daly, A. K. (2017). Pharmacogenetics: A general review on progress to date. *British Medical Bulletin*, 124(1), 65-79.
8. Ellithi, M., Baye, J., & Wilke, R. A. (2020). CYP2C19 genotype-guided antiplatelet therapy: Promises and pitfalls. *Pharmacogenomics*, 21(12), 889-897.

9. Gammal, R. S., & Fieg, E. (2022). Pharmacist and genetic counselor collaboration in pharmacogenomic testing. *Journal of Genetic Counseling*, 31(4), 1298-1312.
10. Gammal, R. S., Lee, Y. M., Petry, N. J., Iwuchukwu, O., Hoffman, J. M., Kisor, D. F., & Empey, P. E. (2022). Pharmacists leading the way to precision medicine: Updates to the core pharmacist competencies in genomics. *American Journal of Pharmaceutical Education*, 86(4), 1-9.
11. Hayashi, M., Hamdy, D. A., & Mahmoud, S. H. (2022). Applications for pharmacogenomics in pharmacy practice: A scoping review. *Research in Social and Administrative Pharmacy*, 18(7), 3094-3118.
12. Hicks, J. K., Aquilante, C. L., Dunnenberger, H. M., Gammal, R. S., Funk, R. S., Aitken, S. L.,... Elder, C. T. (2019). Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice. *Journal of the American College of Clinical Pharmacy*, 2(3), 303-313.
13. Hicks, J. K., Howard, R., Reisman, P., Adashek, J. J., Fields, K. K., Gray, J. E.,... Perkins, R. M. (2021). Integrating somatic and germline next-generation sequencing into routine clinical oncology practice. *JCO Precision Oncology*, 5, 884-895.
14. Ji, Y. (2018). Applications of pharmacogenomics in oncology. *Advances in Molecular Pathology*, 1(1), 115-124.
15. Joly, Y., & Avard, D. (2020). Pharmacogenomics: Ethical, social, and public policy issues. In *The Road from Nanomedicine to Precision Medicine* (pp. 791-827). Jenny Stanford.
16. Lee, C. R., Sriramoju, V. B., Cervantes, A., Howell, L. A., Varunok, N., Madan, S.,... Clarke, M. (2018). Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. *Circulation: Genomic and Precision Medicine*, 11(4), e002069.
17. Luke, M. J., Krupetsky, N., Liu, H., Korenvain, C., Crown, N., Toenjes, S., McCarthy, L. M. (2021). Pharmacists as personalized medicine experts (PRIME): Experiences implementing pharmacist-led pharmacogenomic testing in primary care practices. *Pharmacy*, 9(4), 201.
18. Maduka, C. P., Adegoke, A. A., Okongwu, C. C., Enahoro, A., Osunlaja, O., & Ajogwu, A. E. (2023). Review of laboratory diagnostics evolution in Nigeria's response to COVID-19. *International Medical Science Research Journal*, 3(1), 1-23.
19. Master, Z., Smith, C., & Tilburt, J. C. (2020). Informed consent for stem cell-based interventions. *JAMA*, 323(9), 893-893.
20. Miao, L., Zhang, J., Yi, L., & Huang, S. (2020). The ethical, legal, and regulatory issues associated with pharmacogenomics. *Pharmacogenomics in Precision Medicine: From a Perspective of Ethnic Differences*, 219-239.
21. Okunade, B. A., Adediran, F. E., Maduka, C. P., & Adegoke, A. A. (2023). Community-based mental health interventions in Africa: A review and its implications for US healthcare practices. *International Medical Science Research Journal*, 3(3), 68-91.
22. Orrico, K. B. (2019). Basic concepts in genetics and pharmacogenomics for pharmacists. *Drug Target Insights*, 13, 1177392819886875.
23. Remsberg, C. M., Bray, B. S., Wright, S. K., Ashmore, J., Kabasenche, W., Wang, S.,... Daoud, S. S. (2017). Design, implementation, and assessment approaches within a pharmacogenomics course. *American Journal of Pharmaceutical Education*, 81(1), 11.

24. Rayhan, R., & Rayhan, S. (2023). AI and human rights: Balancing innovation and privacy in the digital age. In DOL.
25. Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S.,... Das, G. (2023). Next-generation sequencing technology: Current trends and advancements. *Biology*, 12(7), 997.
26. Shendure, J., Findlay, G. M., & Snyder, M. W. (2019). Genomic medicine-progress, pitfalls, and promise. *Cell*, 177(1), 45-57.
27. Singh, P. (2023). Pharmacogenomics advances: Customizing drug therapies for individual patients. *Journal of Advanced Research in Pharmaceutical Sciences and Pharmacology Interventions*, 6(1), 21-27.
28. Ta, R., Cayabyab, M. A., & Coloso, R. (2019). Precision medicine: A call for increased pharmacogenomic education. *Personalized Medicine*, 16(3), 233-245.
29. Veilleux, S., & Bouffard, M. (2019). Knowledge and understanding of pharmacogenomic testing among patients and health care professionals: A scoping review. *Patient Education and Counseling*, 102(11), 2001-2009.
30. Veilleux, S., Bouffard, M., & Bourque Bouliane, M. (2020). Patient and health care provider needs and preferences in understanding pharmacogenomic and genomic testing: A meta-data analysis. *Qualitative Health Research*, 30(1), 43-59.
31. Ayo-Farai, O., Olaide, B.A., Maduka, C.P., & Okongwu, C.C. (2023). Engineering innovations in healthcare: A review of developments in the USA. *Engineering Science & Technology Journal*, 4(6), 381-400.
32. Babarinde, A.O., Ayo-Farai, O., Maduka, C.P., Okongwu, C.C., Ogundairo, O., & Sodamade, O. (2023). Review of AI applications in healthcare: Comparative insights from the USA and Africa. *International Medical Science Research Journal*, 3*(3), 92-107.
33. Barker, C. I., Groeneweg, G., Maitland-van der Zee, A. H., Rieder, M. J., Hawcutt, D. B., Hubbard, T. J., & Carleton, B. C. (2022). Pharmacogenomic testing in paediatrics: Clinical implementation strategies. *British Journal of Clinical Pharmacology*, 88*(10), 4297-4310.
34. Bishop, I. R., Schneiderhan, M. E., Butler, T., Carpentier, R. M., Heins, K. R., & Formea, C. M. (2023). Pharmacogenomics to support mental health medication therapy management: Clinical practice considerations and a conceptual framework to enhance patient care. *Journal of the American College of Clinical Pharmacy*.
35. Fahim, S. M., Alexander, C. S. W., Qian, J., Ngorsuraches, S., Hohmann, N. S., Lloyd, K. B., ... & Westrick, S. C. (2023). Current published evidence on barriers and proposed strategies for genetic testing implementation in healthcare settings: A scoping review. *Journal of the American Pharmacists Association*.
36. Fragala, M. S., Shaman, J. A., Lorenz, R. A., & Goldberg, S. E. (2022). Role of pharmacogenomics in comprehensive medication management: Considerations for employers. *Population Health Management*, 25(6), 753-762.
37. Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., & Cervantes, A. (2020). Personalized medicine: Recent progress in cancer therapy. *Cancers*, 12(4), 1009.
38. Hassan, M., Awan, F. M., Naz, A., deAndrés-Galiana, E. J., Alvarez, O., Cernea, A., & Kloczkowski, A. (2022). Innovations in genomics and big data

- analytics for personalized medicine and healthcare: A review. *International Journal of Molecular Sciences*, 23(9), 4645.
39. Jarvis, J. P., Peter, A. P., Keogh, M., Baldasare, V., Beanland, G. M., Wilkerson, Z. T., & Shaman, J. A. (2022). Real-world impact of a pharmacogenomics-enriched comprehensive medication management program. *Journal of Personalized Medicine*, 12(3), 421.
 40. Kabbani, D., Akika, R., Wahid, A., Daly, A. K., Cascorbi, I., & Zgheib, N. K. (2023). Pharmacogenomics in practice: A review and implementation guide. *Frontiers in Pharmacology*, 14, 1189976.

دور علم الوراثة الدوائية في الطب الشخصي: تركيز على تمثيل الأدوية في الجسم الملخص

الخلفية: النهج التقليدي في علاج الأدوية غالبًا ما يعتمد على علاجات موحدة دون مراعاة التباين الفردي في أيض الأدوية. ومع التقدم في علم الصيدلة الجينية، تم تسليط الضوء على أهمية العوامل الوراثية والبيئية في عملية الأيض، مما يوفر نهجًا أكثر تخصيصًا في الطب.

الهدف: يهدف البحث إلى استكشاف دور تباين الأيض في الطب المخصص وكيفية تحسين النتائج العلاجية وتقليل التفاعلات الدوائية السلبية من خلال تخصيص العلاجات بناءً على العوامل الوراثية والبيئية.

الطرق: تم إجراء مراجعة شاملة للأدبيات لفحص تأثير العوامل الوراثية والبيئية على عملية الأيض. كما تم استكشاف دور اختبارات الصيدلة الجينية في تخصيص العلاجات.

يؤثر بشكل كبير على الأيض والفعالية العلاجية والسلامة. كما أن **CYP** النتائج: أظهرت النتائج أن التباين الوراثي في إنزيمات العوامل البيئية مثل النظام الغذائي وأسلوب الحياة تلعب دورًا مهمًا في النتائج العلاجية.

الخلاصة: يعد تباين الأيض من العوامل الأساسية في تطوير العلاجات المخصصة. من خلال دمج اختبارات الصيدلة الجينية في الممارسة السريرية، يمكن تحسين نتائج العلاج وتقليل المخاطر، مما يساهم في تحسين سلامة المرضى وفعالية العلاج.

الكلمات المفتاحية: أيض الأدوية، الصيدلة الجينية، الطب المخصص، التباين الوراثي، التفاعلات الدوائية السلبية، اختبار الصيدلة الجينية.